Sabinsa intends to market the product under the name OcuFors.
Sabinsa (East Windsor, NJ) has received a patent in Japan for a Coleus forskolii–derived natural product targeting glaucoma treatmet. Specifically, the product is a water-soluble form of naturally available diterpenes derived from Coleus forskolii. Sabinsa intends to market the product under the name OcuFors.
“The patent covers both the method for solubilizing diterpenes using randomly methylated beta-cyclodextrin molecules and applications thereof in glaucoma,” the company described in a press release.
It said that compared to the glaucoma drug Timolol, which it described as “a non-selective beta blocker,” OcuFors has been shown to be superior for treating open-angle glaucoma and reducing intraocular pressure.
The company said it is seeking OcuFors’ approval as a glaucoma drug in several other countries, and that OcuFors is the first naturally derived pharmaceutical product that has been approved by the Drug Controller General of India.